Medically Integrated Dispensing (MID)
networks reduce visibility into prescribing HCPs
Leverage real-world oncology data and healthcare analytics to navigate market complexities, refine provider targeting, and optimize oncology drug commercialization strategies.
networks reduce visibility into prescribing HCPs
reduce provider-specific insights
are driving frequent changes in affiliations and reference data
Complex HCP-healthcare organization (HCO) relationships inherent in the oncology space necessitates accurate affiliations data so you can:
Improve incentive compensation allocation and gross-to-net analysis
Optimize targeting of HCPs & HCOs
More effectively deploy sales and marketing resources
Optimize brand presence in light of treatment guidelines
Prioritize efforts based on the changing market landscape
Gain deeper insights and remove knowledge gaps using provider reference and patient claims data crafted for oncology.
Superior provider reference and affiliations data has the power to improve sales and marketing strategies. Our Provider 360 ReadyData™ includes advanced and accurate data on U.S. providers, organizations, and their corresponding affiliations so you can see the relationships between healthcare providers (HCPs), organizations (HCOs), and integrated delivery networks (IDNs).
McKesson Compile™ Provider 360 ReadyData delivers:
of oncology MDs and advanced practice providers
to connect HCP & HCP activity
for real-time accuracy
Inclusion of multiple oncology sources provides strong coverage and accuracy of oncology HCP data
oncologists
coverage of oncology MDs & DOs*
affiliations coverage of oncology MDs & DOs*
affiliations coverage of NP / PAs
“By leveraging the wealth of McKesson’s oncology data, we are helping to bridge the knowledge gaps that exist around where patients receive care and who their care teams are. Ultimately, we want to enable oncology brands to improve patient lives by getting their therapies to the patients that need them.”
A biotech launching a new drug sought to target providers treating patients with a specific type of urologic cancer. Unfortunately, identifying the providers was not easy and required the usage of a combination of data on diagnoses, procedures, and treatment timelines.
The biotech chose McKesson Compile due to the strength of McKesson Compile claims data and incredible customer support. The Real-World Data Analytics (RWDA) team leveraged their expertise in oncology to triangulate insight from patient claims and medical codes found only in EHR data.
McKesson Compile identified more than 20k high-value providers who were treating 270k patients for their launch target list. Using this target list the biotech was able to gain a nearly 20% higher adoption rate than similar drugs in market that used traditional targeting approaches.
The Market Access team at a large pharma company sought to improve patients’ access to treatment for a recently-launched NSCLC drug
After a thorough evaluation of several vendors, the brand chose to partner with McKesson Compile due to:
The robust affiliations data within Provider 360 ReadyData enabled the team to identify the top-treating IDNs, including those they didn’t previously have a view into, so that they could engage in conversations to improve patient access to their therapy.